Registered outcomes36

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 36

List	Outcome	Time frame	Description
Primary	Progression-free survival (PFS) as determined by investigator	After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death)	according to Lugano criteria 2014
Secondary	Complete Response rate (CR) as determined by investigator (CR24)	2 years	according to Lugano criteria 2014
Secondary	Complete response rate (CR) by blinded central review (CR24)	2 years	based on PET result according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) as determined by investigator	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine	according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) as determined by investigator	12 months	according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) as determined by investigator	24 months	according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) as determined by investigator	36 months	according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) as determined by investigator	48 months	according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) as determined by investigator	60 months	according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) by blinded central review	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine	based on PET result according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) by blinded central review	12 months	based on PET result according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) by blinded central review	24 months	based on PET result according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) by blinded central review	36 months	based on PET result according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) by blinded central review	48 months	based on PET result according to Lugano Criteria 2014
Secondary	Overall response rate (ORR) by blinded central review	60 months	based on PET result according to Lugano Criteria 2014
Secondary	CR rate other than CR24 as determined by investigator	6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine	according to Lugano Criteria 2014
Secondary	CR rate other than CR24 as determined by investigator	12 months	according to Lugano Criteria 2014
Secondary	CR rate other than CR24 as determined by investigator	24 months	according to Lugano Criteria 2014
Secondary	CR rate other than CR24 as determined by investigator	36 months	according to Lugano Criteria 2014
Secondary	CR rate other than CR24 as determined by investigator	48 months	according to Lugano Criteria 2014

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06006117/registered

API reference For AI assistants

Registered outcomes36

Sources 3

Read this list from software.